Form 4: Director Parag Saxena Granted RVPH Stock Options

Reviva Pharmaceuticals Holdings, Inc. director Parag Saxena received 8,200 stock options with an exercise price of $0.5848, vesting in one year.

Summary

• Parag Saxena, a director of Reviva Pharmaceuticals Holdings, Inc. (RVPH), was granted 8,200 stock options.
• The options have an exercise price of $0.5848 per share.
• The grant date for these options was December 18, 2025.
• The options will vest 100% on the one-year anniversary of the grant date, provided Mr. Saxena remains a director of the company.
• The options expire on December 17, 2035.
• This award was made under the company's 2020 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice designed to align management interests with shareholders. It does not contain any unexpected positive or negative news.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $0.5848 is based on the closing price on the grant date, indicating a standard compensation practice.

Negatives

• The options do not provide immediate liquidity or direct ownership of shares until vested and exercised.
• The value of the options is contingent on the future stock price exceeding the exercise price.

Risks

• The options are subject to a vesting condition, requiring the reporting person to remain a director for one year.
• The value of the options can be negatively impacted if the company's stock price does not appreciate above the exercise price of $0.5848.
• Market volatility could reduce the potential profitability of the options.

Future Outlook

The grant of stock options implies an expectation that the company's stock price will appreciate over the vesting and exercise period, making the options valuable for the director.

Industry Context

N/A

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with those of shareholders, potentially leading to better performance.
• Director (Parag Saxena): Receives potential future equity upside, contingent on company performance and continued service.

Next Steps

• The options will vest 100% on December 18, 2026, provided Parag Saxena remains a director.
• Following vesting, the director may choose to exercise the options at the specified exercise price before the expiration date of December 17, 2035.

Key Dates

Keywords

Reviva Pharmaceuticals Holdings Inc., RVPH, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Form 4, Parag Saxena